IRadimed Q2 FY26 GAAP diluted EPS drops 9% to $0.41; revenue rises 0.5% to $20.5 million - IRMD News | RalliesIRadimed Q2 FY26 GAAP diluted EPS drops 9% to $0.41; revenue rises 0.5% to $20.5 million
I
IRMD• Q2 results
- IRadimed posted Q2 GAAP diluted EPS of $0.41, down 9% year over year, as revenue edged up 0.5% to $20.5 million.
- Net income fell 10% to $5.2 million; gross margin narrowed 4 percentage points to 74%.
- Non-GAAP diluted EPS was $0.46, down 7%; cash flow from operations dropped 23% to $5.9 million.
Product launch and outlook
- Launched the new 3870 MR IV pump, with initial shipments meeting plan; said domestic monitor unit bookings set a record.
- Forecast Q3 revenue of $23 million-$24.5 million; reaffirmed full-year revenue guidance of $91 million-$96 million.
ZBAO
•
